CTLA4 and head and neck squamous cell carcinoma: In this review, we summarized the potential of modulating the TME after the administration of these targeted agents, discuss subsequent therapies, and suggest a reasonable combination therapy using cetuximab and an anti-CTLA-4 antibody that should be evaluated in the future as a breakthrough therapy for HPD of HNSCC including R/M diseases.